What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Leukemia
Hagop M. Kantarjian spends much of his time researching Internal medicine, Leukemia, Gastroenterology, Myeloid leukemia and Surgery.
Hagop M. Kantarjian has researched Internal medicine in several fields, including Immunology and Oncology.
His Leukemia research is multidisciplinary, incorporating elements of Myeloid, Myelodysplastic syndromes and Pharmacology.
Within one scientific family, he focuses on topics pertaining to Chemotherapy under Gastroenterology, and may sometimes address concerns connected to Acute promyelocytic leukemia.
His studies deal with areas such as Adverse effect and Fms-Like Tyrosine Kinase 3 as well as Myeloid leukemia.
Hagop M. Kantarjian works mostly in the field of Chronic myelogenous leukemia, limiting it down to topics relating to Philadelphia chromosome and, in certain cases, Acute lymphocytic leukemia, as a part of the same area of interest.
His most cited work include:
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia (4424 citations)
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2888 citations)
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2837 citations)
What are the main themes of his work throughout his whole career to date?
Hagop M. Kantarjian mainly investigates Internal medicine, Oncology, Myeloid leukemia, Gastroenterology and Leukemia.
His work carried out in the field of Internal medicine brings together such families of science as Surgery and Immunology.
His Oncology research is multidisciplinary, incorporating perspectives in Transplantation, Cancer, Myelodysplastic syndromes and Decitabine.
He combines subjects such as Tyrosine kinase and Bone marrow with his study of Myeloid leukemia.
His studies in Gastroenterology integrate themes in fields like Refractory, Phases of clinical research, Adverse effect, Neutropenia and Myelofibrosis.
His biological study spans a wide range of topics, including Myeloid and Pharmacology.
He most often published in these fields:
- Internal medicine (70.44%)
- Oncology (32.15%)
- Myeloid leukemia (27.24%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (70.44%)
- Oncology (32.15%)
- Myeloid leukemia (27.24%)
In recent papers he was focusing on the following fields of study:
Hagop M. Kantarjian focuses on Internal medicine, Oncology, Myeloid leukemia, Cancer research and In patient.
His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology.
The Oncology study combines topics in areas such as Chemotherapy, Blinatumomab, Lymphoblastic Leukemia, Decitabine and Transplantation.
His work deals with themes such as Refractory, Myeloid, Azacitidine, Venetoclax and Bone marrow, which intersect with Myeloid leukemia.
Hagop M. Kantarjian interconnects Tyrosine kinase, Mutant and Stem cell in the investigation of issues within Cancer research.
The various areas that Hagop M. Kantarjian examines in his Leukemia study include Cancer and Clinical trial.
Between 2017 and 2021, his most popular works were:
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. (571 citations)
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML (526 citations)
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study (291 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Internal medicine, Oncology, Myeloid leukemia, Leukemia and Gastroenterology are his primary areas of study.
His Oncology research integrates issues from Hematopoietic stem cell transplantation, Transplantation, Phases of clinical research, Philadelphia chromosome and Blinatumomab.
His Philadelphia chromosome research includes elements of Nilotinib, Ponatinib and Dasatinib.
His research in Myeloid leukemia focuses on subjects like Azacitidine, which are connected to Febrile neutropenia and Myelodysplastic syndromes.
His Leukemia research incorporates themes from Survival rate, Cancer and Clinical trial.
His Gastroenterology study combines topics from a wide range of disciplines, such as Hypomethylating agent and Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
